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Abstract
Background: HCV coinfection remains a major cause of morbidity and mortality among
HIV-infected individuals and its incidence has increased dramatically in HIV-infected men
who have sex with men(MSM).
Methods: Hepatitis C virus (HCV) coinfection in the Swiss HIV Cohort Study(SHCS) was
studied by combining clinical data with HIV-1 pol-sequences from the SHCS Drug Resist-
ance Database(DRDB). We inferred maximum-likelihood phylogenetic trees, determined
Swiss HIV-transmission pairs as monophyletic patient pairs, and then considered the dis-
tribution of HCV on those pairs.
Results: Among the 9748 patients in the SHCS-DRDB with known HCV status, 2768(28%)
were HCV-positive. Focusing on subtype B(7644 patients), we identified 1555 potential
HIV-1 transmission pairs. There, we found that, even after controlling for transmission
group, calendar year, age and sex, the odds for an HCV coinfection were increased by an
odds ratio (OR) of 3.2 [95% confidence interval (CI) 2.2, 4.7) if a patient clustered with an-
other HCV-positive case. This strong association persisted if transmission groups of
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intravenous drug users (IDUs), MSMs and heterosexuals (HETs) were considered separ-
ately(in all cases OR >2). Finally we found that HCV incidence was increased by a hazard
ratio of 2.1 (1.1, 3.8) for individuals paired with an HCV-positive partner.
Conclusions: Patients whose HIV virus is closely related to the HIV virus of HIV/HCV-
coinfected patients have a higher risk for carrying or acquiring HCV themselves. This
indicates the occurrence of domestic and sexual HCV transmission and allows the identi-
fication of patients with a high HCV-infection risk.
Key words: HIV-HCV coinfection, molecular epidemiology, genotypic resistance testing, sexual transmission
of HCV
Introduction
Hepatitis C virus (HCV) is one of the major causes of
chronic liver disease. Overall 3% of the world population
are infected with HCV.1 Of those infected, 20–50%
develop liver cirrhosis and 5% hepatocellular carcin-
oma.2,3 The epidemics of HIV and HCV interact in
multiple ways. Accordingly, a substantial fraction of
HIV-infected individuals also carry HCV. Both viruses
can be transmitted parenterally by contaminated blood
(needlesticks, blood transfusions etc.) or sexually. How-
ever, the efficiency of these transmission routes differs
strongly between the two viruses. HCV is more efficiently
transmitted by needlesticks than HIV(approximately by a
factor of 10)4 whereas its transmission rate upon sexual
contact is much lower. Several studies have even ques-
tioned the epidemiological importance of sexual transmis-
sion for HCV.5 Accordingly, HIV-HCV coinfections in
Western Europe occurred, until recently, almost exclu-
sively in intravenous drug users (IDU). In recent years,
however, HCV incidence has increased dramatically in
HIV-infected men who have sex with men (MSM).6–10 The
mechanisms behind this development are unclear (e.g. in-
crease in traumatic sexual practices,9 decreased condom
use11 etc.) and non-injecting drug consumption may also
constitute a transmission route.9 Nevertheless, the accumu-
lated evidence6–10 indicates an increased role of sexual
transmission for HCV in HIV-infected patients.
Despite the shared transmission mechanisms, it is
unclear to what extent the two viruses also share entire
transmission networks. The Swiss HIV Cohort Study
(SHCS) is a unique research tool for studying how the HIV
and HCV epidemics interact. First, it is unique in terms of
its representativeness of the HIV epidemic in an entire
country. Specifically, it includes an estimated 45% of all
HIV-infected patients in Switzerland (since 1988) and
represents all major risk groups (MSM, IDU, HET) and
geographical regions in Switzerland.12 Second, since 1998,
HCV-negative individuals in the SHCS have been screened
at least every 2 years for HCV. This allows a detailed
estimation of HCV incidence and prevalence in the HIV-
infected population in Switzerland. Finally, the SHCS is
linked to the SHCS-Drug-Resistance Database (SHCS-
DRDB) which contains >15 000 sequences from >10 000
patients in the SHCS. This allows combining molecular
epidemiology approaches with the traditional epidemiolo-
gical analysis of disease spread.
Molecular epidemiology approaches have made import-
ant contributions to understanding the spread of infectious
diseases such as HIV-1.13–19 The molecular epidemiology of
HIV-1 has been facilitated by the fact that HIV-1 sequences
are routinely generated in the context of genotypic drug re-
sistance tests. By contrast, only few HCV sequences are
available for most HCV epidemics, which limits classical
molecular epidemiology analyses. Here, we study the
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• This approach represents a novel method for identifying HIV-infected individuals with a high risk for HCV
coinfections.
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interaction between the spreads of HIV and HCV in Switz-
erland by analysing the distribution of HCV cases on the
population-level phylogeny of HIV. This population-level
phylogeny describes the clustering of HIV sequences from
different patients and characterizes thereby the transmission
chains of HIV. Accordingly, we expect the degree of cluster-
ing of HCV on this phylogeny to be a measure of the inten-
sity of the interaction between the HIV and HCV epidemics.
Methods
We explored the spread of HCV among HIV-infected indi-
viduals in Switzerland by combining clinical and demo-
graphic data from the SHCS with HIV-1 nucleotide
sequences (partial pol gene: entire protease and partial
reverse transcriptase) from the SHCS-DRDB. The SHCS is
a nationwide, prospective, clinic-based cohort study with
continuous enrolment and semi-annual study visits (cur-
rently over 17 000 patients enrolled).12,20,21 The SHCS has
been approved by ethical committees of all participating
institutions and written informed consent has been ob-
tained from participants. The SHCS-DRDB includes the
genotypic drug resistance test results generated in the con-
text of the SHCS: all 4 laboratories allowed to perform re-
sistance testing in Switzerland contribute all their
resistance test results to the SHCS-DRDB. Furthermore,
retrospective sequencing was performed systematically
from the sample repository to obtain a sequence for all pa-
tients since 1996. In total, the SHCS-DRDB contains
15 626 sequences from 10 139 patients. HCV status was
known for 9748/10 139 patients. From these, we used for
the phylogenetic part of the analysis the earliest sequence
of each patient infected with HIV-1 subtype B (7644 se-
quences; download: 26 November 2012). We pooled these
sequences with all corresponding available subtype B se-
quences from the Los-Alamos sequence database (36 227
sequences, criteria for selecting these sequences: entire
protease had to be available and sequence length had to ex-
ceed 1000 nucleotides; download: 26 November 2012).
From this pooled dataset, we inferred maximum-likeli-
hood phylogenetic trees with FastTree 222 (assuming the
GTR model of molecular evolution). Codons, where major
drug resistance mutations occur (codons 30, 32, 33, 46, 47,
48, 50, 54, 76, 82, 84, 88 and 90 in the PR, and 41, 62, 65,
67, 69, 70, 74, 75, 77, 100, 103, 106, 108, 115, 116, 151,
181, 184, 188, 190, 210, 215, 219, 225 and 236 in the RT)
were excluded from the analysis in order to avoid distortion
by convergent evolution. FastTree was used to infer the
phylogeny because it is considerably faster than RaxML23
and has been shown to exhibit only ‘little and (in some cases
no) degradation in tree accuracy, as compared to
RAxML’24. We determined on these trees potential Swiss
HIV-transmission pairs as monophyletic pairs of Swiss
patients (see Figure 1 for a schematic representation; see
also supplementary material for an extension of this ap-
proach to larger clusters, available as Supplementary data at
IJE online). Then we analysed the distribution of HCV cases
on the tree and the potential transmission pairs using uni-
variable and multivariable logistic regression models.
Positive HCV tests were determined by either positive
HCV serology[enzyme-linked immunosorbent assay
(ELISA) confirmed by immunoblotting] or by detectable
Figure 1. Schematic representation of the rationale of the phylogenetic analysis. (A) In the first step, the Swiss sequences from the SHCS-DRDB are
pooled with all available foreign sequences from the Los-Alamos Sequence Database and a phylogenetic tree is inferred (red tips: Swiss sequences;
black tips: non-Swiss sequences; note that in the real tree, most sequences are non-Swiss). (B) In the second step, Swiss transmission pairs are
inferred as monophyletic pairs of Swiss sequences (indicated by orange ellipses). Note that in this analysis, we discarded sequences that belong to
pairs with foreign sequences (such as sequence d1) and sequences that are not part of monophyletic pairs (such as d2 and d3). In the supplementary
material (available as Supplementary data at IJE online) we present an analysis that also includes such sequences discarded in the main analysis.
(C) In the third step, we consider the distribution of HCV states over the transmission pairs. Three constellations are possible: HCV-sero-concordant
and -positive (upper pair), HCV-sero-concordant and -negative (middle pair) and HCV-sero-discordant (lower pair).
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HCV RNA (RT-PCR).10 Every patient with at least one
positive HCV test was considered a prevalent case. Patients
whose first HCV test was negative were considered inci-
dent cases if they tested HCV-positive in subsequent tests.
Given that direction of transmission was typically not
known, we considered for a given pair (consisting of pa-
tients P1 and P2) the HCV status of each patient both as a
potential exposure and an outcome. If the HCV status of
patient P1 was considered as the outcome, the HCV status
of P2 was the exposure variable and vice versa. Biologi-
cally, one can interpret the HCV status of the ‘exposure
patient’ as a proxy for the HCV frequency in the transmis-
sion network of the outcome patient (see Discussion). In
order to take into account the resulting non-independence
of the data points, we used in our regression models robust
standard errors (based on the clustering of the patients).
We distinguished between the three traditional HIV
transmission groups: MSMs,IDUs) and HETs. Given that
intravenous drug use is considered to be a far stronger risk
factor for HCV transmission than sexual contacts (see
Table 1 and reference 4), we considered those HETs and
MSMs for which intravenous drug use was reported (but
not as the likely route of HIV transmission) as the follow-
ing separate risk groups: HET-I (individuals who stated
having acquired HIV heterosexually but also reported
intravenous drug use) and MSM-I (men who stated having
acquired HIV by homosexual contact but also reported
intravenous drug use).
The impact of phylogenetic status on the incidence of
HCV (i.e. the hazard with which initially HCV-negative in-
dividuals acquired HCV) was determined using univariable
and multivariable Cox proportional hazard models. In
these models, the time of the first negative HCV test was
chosen as the time-origin for each patient. The propor-
tional hazards assumption was tested by Schoenfeld re-
siduals and it could not be rejected (at P> 0.05).
Results
Among the 9748 individuals in the SHCS-DRDB with
information on their HCV status, 2768 (28.4%) had
at least one positive HCV test and were classified as
HCV-prevalent cases, and 208 (2.1%) had a first negative
and a subsequent positive HCV test and were classified as
incident cases. HCV prevalence differed strongly across
risk groups. Specifically, 2038/2147 (94.9%) IDUs, 200/
3167 (6.3%) HETs and 190/3568 (5.3%) MSMs had at
least one positive HCV test. Further, 318 HETs and 162
MSMs reported previous intravenous drug use and were
classified as separate risk groups (HET-I and MSM-I).
HET-I and MSM-I individuals exhibited a much larger
HCV prevalence than the remaining HETs and MSMs
(71.7% for HET-I vs 6.3% for HET, and 27.2% for
MSM-I vs 5.3% for MSM), which is consistent with the
fact that intravenous drug use is a much more efficient
transmission route for HCV than sexual contact. Other
risk-groups (perinatal, blood transfusion etc.) contributed
386 patients (4%; 318 HCV-negative, 68 HCV-positive),
who were excluded from further analysis. The baseline
characteristics of the remaining study population (9362 pa-
tients) are summarized in Table 1.
We found that HCV status was strongly associated with
HIV subtype (Table 1). Overall, >90% of HCV cases
occurred in individuals with HIV-1 subtype B, and hence
we restricted the phylogenetic part of the analysis to this
subtype. Nevertheless it should be noted that, at least in
Switzerland, a non-B subtype HIV-1 infection implies a
lower risk of an HCV coinfection than a subtype B HIV in-
fection [adjusted OR¼ 0.5 (0.4, 0.6), see Table 1]. The
main reason for the difference between subtypes is their
composition in terms of transmission groups. As we have
shown previously,14 all three main transmission groups
(HETs, MSMs and IDUs) are well represented among indi-
viduals with a HIV-1 subtype B infection. By contrast,
infections with non-B HIV-1 are limited almost exclusively
to HETs.12,20,21 We found a similar difference in the distri-
bution of transmission groups for B and non-B HIV-1
subtypes among individuals included in this study (see
Table S1, available as Supplementary data at IJE online).
Thus the major drivers of HCV transmission (IDU in the
past and MSM in the present) are missing from non-B sub-
types, explaining the difference in HCV prevalence. This
indicates that the HCV epidemic in Switzerland is more
closely connected to the transmission networks of HIV-1
subtype B than to those of non-B subtypes.
For subtype-B HIV infections, we considered the clus-
tering of Swiss HCV cases on the HIV phylogeny derived
from 7644 Swiss and 36 227 non-Swiss pol sequences (see
Methods and Figure 1). On this phylogeny, we could iden-
tify 1555 potential HIV-1 transmission pairs, for which the
HCV status was known for both members. In 907, 303
and 345 of these pairs none, one and both patients were
HCV–infected, respectively. This implies that for a patient
in a given transmission pair, the odds of having a HCV
coinfection was increased by an OR of 13.6 [95% CI
(10.5, 17.6)] if the other patient in the pair had an HCV
coinfection as well. This extremely high OR was largely
due to the tendency of IDUs to cluster with other IDUs.14
Since most HCV cases occurred in IDUs, this clustering of
IDUs with each other resulted in a strong confounding of
the OR by patient risk group. However, a strong associ-
ation between the HCV status of the patients in a transmis-
sion pair persisted, even if risk groups were considered
separately. Specifically, the ORs were 5.4 (2.9, 10.3) for
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HETs, 2.7 (1.3, 5.5) for IDUs, 3.1 (1.4, 7.0) for MSMs,
2.1 (0.9, 5.1) for HET-I and 4.5 (1.2, 16.3) for MSM-I.
In terms of HCV prevalence, this implies for example that
among MSMs that were paired with HCV-negative
patients, the prevalence was 4.1% but increased to 11.8%
for MSMs that were paired with HCV-positive patients.
When adjusted for sex, age, risk group, year of registra-
tion in the SHCS, and treatment center (¼ proxy for geo-
graphical location), in a multivariable analysis, we also
found that patients in transmission pairs were much more
likely to be HCV-positive if their partner in the pair was
HCV-positive [OR 3.2 (2.2, 4.7), see table 2]. Thus, we
observed a strong clustering of prevalent HCV cases on the
HIV phylogeny even after controlling for the most import-
ant demographic confounders.
The extent to which the HCV status of neighbouring
patients could predict the risk of an HCV infection
depended on the strength of phylogenetic linkage: if
restricted to pairs with high local support values on the
HIV phylogeny, the degree of HCV clustering became even
stronger. Specifically, if the analysis was restricted to pairs
with Shimodaira-Hasegawa-support values22 exceeding
0.7, 0.9, 0.95 and 0.99, we found in the multivariable ana-
lysis ORs of 3.4 (2.2, 5.3), 3.4 (1.9, 6.2), 4.0 (1.8, 9.2) and
4.7 (0.97, 22.4), respectively. On the other hand, we ex-
tended the classification into high- and low-risk patients
beyond transmission pairs. For these patients phylogenetic
linkage was weaker than for transmission pairs, but still re-
sulted in a strong predictor of HCV infection [OR 2.1(1.7,
2.6), see supplementary material available as Supplemen-
tary data at IJE online).
For incident HCV cases, we found that those HCV-
negative HIV patients that belonged to a transmission-pair
in which the other patient was HCV-positive had a higher
Table 1. Baseline characteristics of the study population consisting of individuals from the SHCS-DRDB with at least one HCV
test available
Characteristic HCV- (%) HCVþ (%) Total OR (95% CI) for HCVþ in
univariate model
OR (95% CI) for HCVþ in
multivariate model
Transmission group
HET 2967 (93.7) 200 (6.3) 3167 Baseline Baseline
HET-I 90 (28.3) 228 (71.7) 318 37.6 (28.3, 49.9) 27.8 (20.6, 37.5)
IDU 109 (5.1) 2038 (94.9) 2147 277.4 (218.2, 352.6) 179.1 (138.7, 231.1)
MSM 3378 (94.7) 190 (5.3) 3568 0.8 (0.7, 1) 0.6 (0.5, 0.7)
MSM-I 118 (72.8) 44 (27.2) 162 5.5 (3.8, 8) 4 (2.7, 6.1)
HIV subtype
B 4748 (65.5) 2506 (34.5) 7254 Baseline Baseline
Non-B 1914 (90.8) 194 (9.2) 2108 0.2 (0.2, 0.2) 0.5 (0.4, 0.6)
Sex
Male 4922 (73.5) 1777 (26.5) 6699 Baseline Baseline
Female 1740 (65.3) 923 (34.7) 2663 1.5 (1.3, 1.6) 0.9 (0.7, 1.1)
Centre
Zurich 2755 (72.6) 1041 (27.4) 3796 Baseline Baseline
Basel 695 (70.6) 289 (29.4) 984 1.1 (0.9, 1.3) 1 (0.8, 1.3)
Bern 782 (67.1) 383 (32.9) 1165 1.3 (1.1, 1.5) 1 (0.8, 1.4)
Geneva 997 (76.9) 300 (23.1) 1297 0.8 (0.7, 0.9) 0.7 (0.6, 1)
Lausanne 935 (72.1) 361 (27.9) 1296 1 (0.9, 1.2) 1.3 (1, 1.6)
Lugano 167 (60.7) 108 (39.3) 275 1.7 (1.3, 2.2) 1.7 (1, 2.6)
St Gallen 331 (60.3) 218 (39.7) 549 1.7 (1.4, 2.1) 1.3 (0.9, 1.8)
Registration year
–1989 257 (40.1) 384 (59.9) 641 Baseline Baseline
1990–94 790 (53.6) 685 (46.4) 1475 0.6 (0.5, 0.7) 0.8 (0.6, 1.2)
1995–99 1789 (66) 921 (34) 2710 0.3 (0.3, 0.4) 0.6 (0.4, 0.8)
2000–04 1563 (78) 441 (22) 2004 0.2 (0.2, 0.2) 0.6 (0.4, 0.8)
2005– 2263 (89.4) 269 (10.6) 2532 0.1 (0.1, 0.1) 0.3 (0.2, 0.5)
Age at registration (years)
–29 1573 (60.9) 1008 (39.1) 2581 Baseline Baseline
30–39 2673 (67.9) 1264 (32.1) 3937 0.7 (0.7, 0.8) 1.2 (1, 1.5)
40–49 1534 (81.1) 358 (18.9) 1892 0.4 (0.3, 0.4) 1.2 (0.9, 1.5)
50–59 600 (91.7) 54 (8.3) 654 0.1 (0.1, 0.2) 1.1 (0.8, 1.6)
60– 282 (94.6) 16 (5.4) 298 0.1 (0.1, 0.1) 0.8 (0.5, 1.5)
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rate of acquiring HCV than those paired with an HCV-
negative partner (Figure 2). Specifically, we found a hazard
ratio (HR) of 2.5 (1.5, 4.2) in a univariable Cox propor-
tional hazards model. In the corresponding multivariable
analysis adjusted for risk and calendar year, the corres-
ponding HR was 2.1 (1.1, 3.8) (Table 3). The covariates
included in this multivariable model differed for the fol-
lowing reasons from the ones included in the analysis of
prevalent cases (Table 2). First, it has been shown that the
incidence of HCV dramatically increased over the past
year for MSMs but decreased for IDUs.10 Therefore we
included calendar year as a separate variable for MSMs
and non-MSMs (indeed, Table 3 shows that the hazard for
an HCV infection decreased over calendar time for non-
MSMs but substantially increased for MSMs). Secondly,
we had to reduce the number of variables in the model be-
cause only 75 incident HCV cases occurred in transmission
Table 2. Multivariable logistic regression model for HCV prevalence in patients included in HIV trans-
mission pairs (odds ratios are adjusted for all variables listed)
Patients No. (%) Odds ratio (95% CI) P-value
HCV Status of Partner in Pair
HCV-neg 2,047 (67.9) Baseline
HCV-pos 966 (32.1) 3.2 (2.2, 4.7) <0.001
transmission group
HET 651 (21.6) Baseline
HET-I 119 (4) 27.3 (15.6, 47.7) <0.001
IDU 781 (25.9) 180.2 (112.5, 288.7) <0.001
MSM 1,387 (46) 0.9 (0.6, 1.5) 0.764
MSM-I 75 (2.5) 4.2 (2.1, 8.6) <0.001
Sex
male 2,365 (78.5) Baseline
female 648 (21.5) 1.1 (0.7, 1.6) 0.817
Center
Zurich 1,338 (44.4) Baseline
Basel 326 (10.8) 0.9 (0.5, 1.6) 0.694
Bern 376 (12.5) 1.1 (0.7, 1.7) 0.608
Geneva 334 (11.1) 1 (0.7, 1.6) 0.854
Lausanne 355 (11.8) 1.4 (0.8, 2.2) 0.209
Lugano 74 (2.5) 1.2 (0.5, 2.8) 0.746
St. Gallen 210 (7) 1.2 (0.7, 2.1) 0.53
Registration Year
–1989 208 (6.9) Baseline
1990–1994 462 (15.3) 0.8 (0.4, 1.6) 0.583
1995–1999 880 (29.2) 0.6 (0.3, 1.2) 0.154
2000–2004 632 (21) 0.4 (0.2, 0.8) 0.013
2005– 831 (27.6) 0.3 (0.2, 0.6) <0.001
age at registration
–29 831 (27.6) Baseline
30–39 1,277 (42.4) 1.3 (0.9, 2) 0.117
40–49 636 (21.1) 1.1 (0.7, 1.8) 0.728
50–59 183 (6.1) 1 (0.5, 2.1) 0.978
60– 86 (2.9) 1.7 (0.6, 4.6) 0.281
Figure 2. Kaplan_Meyer estimates for HCV incidence in patients paired
with HCV-positive (red) and HCV-negative patients (blue) on the HIV phyl-
ogeny. In the risk-table below the x-axis, N refers to individuals with an
HCV-negative partner and P to individuals with an HCV-positive partner.
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pairs. For this reason, we omitted the variables ‘age’, ‘sex’
and ‘centre’, which only had a weak impact on prevalent
cases, and treated ‘calendar year’ as a continuous variable.
We found however almost the same impact of the HCV
status in the transmission-pair partner when including the
same covariates as for prevalent cases [HR 2.2 (1.2, 4.1)].
Finally, we found a comparable HR for the impact of HCV
exposure if we restricted the multivariable analysis to
MSMs, at 2.29 (0.9, 5.4). This suggests that the observed
doubling of HCV incidence in individuals clustering with
HCV-coinfected partners on the HIV phylogeny was, at
least in part, mediated through sexual transmission of
HCV.
Finally, we considered the distribution of HCV geno-
types on the HIV phylogeny. HCV genotype information
was available for 1302 patients infected with HIV-1 sub-
type B in the SHCS-DRDB. This resulted in 99 transmis-
sion pairs for which HCV genotype information was
available for both members. The most frequent HCV geno-
types were 1A (n¼ 370), 3A (n¼ 361), 1B (n¼ 192), and
4C/4D (n¼ 105). Taking this genotype information into
account, we found pairings with consistent genotypes in 39
out of 99 pairs. We assessed whether this pattern was
stronger than expected by chance by comparing it with
the genotype concordance after randomizing the genotypes
of the 99 transmission pairs that had genotype information
for both members (104 replicates). This randomization
test revealed that the observed degree of genotype cluster-
ing exceeded the genotype concordance expected by
chance (P¼ 0.007). Across randomizations, the median
(95% CI) number of pairs with consistent genotypes was
28 (20, 36); thus the observed number of pairs with con-
sistent genotypes exceeded the expectation by a factor of
1.4 (1.1, 2.0).
Despite the fact that genotypes clustered more strongly
than expected by chance (with P¼ 0.007), the overall
strength of this clustering was relatively weak. This indi-
cates that the clustering of HCV cases on the HIV phyl-
ogeny was caused by both direct and indirect mechanisms
(see Discussion). However, the weak genotype clustering
might also reflect the fact that individual patients have
experienced multiple, subsequent HCV infections and
might therefore have switched their HCV genotype. Of
217 patients with more than one HCV genotype measure-
ment, 13 experienced a switch in HCV genotype, which
corresponded to a genotype switching rate of 1/49.6 pa-
tient-years. This might be a strong underestimate of the fre-
quency of superseding HCV infections that occurred in the
1980s/90s (when most IDUs acquired their HCV infection)
because, on the one hand, patients reduce their risk behav-
iour once an HIV infection is diagnosed25 and, on the other
hand, the risk of HCV transmissions among IDUs in Switz-
erland has strongly decreased over the past years as a result
of needle-exchange programmes. This hypothesis is sup-
ported by the fact that HCV superinfections have been
shown to be frequent in other settings (without IDU-
targeted prevention efforts comparable to Switzerland).26
Thus the relatively weak clustering of HCV genotypes as
compared with the clustering of HCV cases might reflect a
very dynamic early HCV epidemic with frequent HCV sub-
type substitutions.
Discussion
Even though prevention efforts in the past two decades
have been successful in some high-risk populations,10 the
spread of HCV is still a major public health concern.5
The recent spread of HCV among HIV-infected MSMs is
Table 3. Multivariable Cox proportional hazard model for incident HCV cases (odds ratios are adjusted for all variables listed).
The time of the first negative HCV-test was chosen as the time-origin for each patient. The proportional hazards assumption
was tested by Schoenfeld residuals and it could not be rejected (P> 0.5)
Patient At risk, No. (%) No. of incident cases (%) Hazard ratio (95%CI) P
HCV Status of Partner in Pair
HCV-neg 1,567 (85.2) 49 (65.3) Baseline
HCV-pos 272 (14.8) 26 (34.7) 2.1 (1.1, 3.8) 0.018
transmission group
HET 528 (28.7) 4 (5.3) Baseline
HET-I 28 (1.5) 4 (5.3) 16.2 (3.9, 67.3) <0.001
IDU 47 (2.6) 22 (29.3) 49.5 (16.1, 151.7) <0.001
MSM 1,182 (64.3) 40 (53.3) 1.3 (0.3, 4.8) 0.719
MSM-I 54 (2.9) 5 (6.7) 13.3 (3.6, 49.5) <0.001
Calendar Year
for MSMs 1.2 (1.1, 1.3) 0.002
for non-MSMs 0.9 (0.8, 1.0) 0.073
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especially worrisome as it underlines the dynamic and
adaptable nature of the HCV epidemic. Whereas the de-
crease of HCV transmission among IDUs can be attributed
to the public health measures addressed to this transmis-
sion group (needle-exchange programmes, methadone and
heroin-substitution programmes etc.),10 the reasons under-
lying the increase of HCV among MSMs are much less cer-
tain. The fact that incident HCV infections occur
preferentially in MSMs with high-risk sexual behaviour,9
the association of HCV with other sexually transmitted in-
fections (STIs)10 and the recent decrease in condom use11
suggest however that the rise of HCV among MSMs may
be due to increased risk-taking in this transmission group.
Therefore it is crucial to understand the interaction be-
tween HIV and HCV and to be able to identify high-risk
populations for the spread of HCV beyond the obvious
candidates (such as IDUs).
Our finding that HCV-cases cluster on the HIV-
phylogeny, even after taking the most important demo-
graphic variables into account, can be interpreted in two
ways. The direct interpretation explains the clustering by
the fact that HIV and HCV directly share transmission
routes. A clustering of two patients on the HIV phylogeny
implies a proximity on the contact network (defined by
those transmission routes), and hence also on the contact
network on which HCV can spread. In other words, two
individuals who cluster on the HIV phylogeny are also
more likely to belong to the same HCV transmission chain.
The indirect interpretation explains the clustering by as-
sortative mixing of high-risk subpopulations. It is a general
feature of the molecular epidemiology of HIV that patients
cluster preferentially with other patients of the same demo-
graphic and social strata.14,20 Accordingly, if some classes
are more prone to be infected with HCV, then HCV cases
and hence also their neighbours on the HIV phylogeny will
more likely belong to those classes. The multivariable ana-
lyses (Tables 2 and 3) partially adjust for this effect, but
other demographic variables, such as belonging to a local
high-risk population, may cause an additional clustering of
HCV cases on the HIV phylogeny. Our finding that indi-
vidual HCV genotypes clustered more strongly than ex-
pected by chance (with P¼ 0.007) but that the magnitude
of this effect was weak, indicates that both the direct and
the indirect mechanisms are responsible for the clustering
of HCV cases on the HIV phylogeny.
Whatever the underlying reasons for the clustering of
HCV on the HIV phylogeny, our results indicate that the
transmission networks of HIV and HCV are correlated
and overlap even beyond the degree that can be expected
by demographic variables such as riskgroup (especially
IDUs), geography, sex and age. Thus, our analysis shows
that the location of an HIV-infected patient on the HIV
phylogeny can serve as an indicator for the risk of an
HCV coinfection: Patients whose HI virus is closely related
to the HI virus of HIV/HCV coinfected patients have a
higher risk of carrying HCV themselves and, if they are
HCV-negative, they have a higher risk of becoming in-
fected with HCV. Accordingly, such patients could consti-
tute target groups where intensified testing and counselling
are particularly important. Alternatively, the phylogenetic
information could be integrated with other information
such as high-risk sexual practices9 (information not avail-
able in our dataset) to derive a combined risk assessment
score.
This study has several limitations. First, the method to
detect clustering of HCV cases is only indirect. Instead of
directly observing clusters of Swiss HCV cases on a phyl-
ogeny from HCV sequences, we consider the distribution
of HCV sequences on the HIV phylogeny. As outlined
above, this type of clustering is consistent both with shared
transmission networks and with a clustering of risk factors
(for HCV acquisition) on the HIV phylogeny. A direct
quantification of the fraction of domestically transmitted
HCV infections would require sequencing HCV from in-
fected patients and goes therefore beyond the scope of this
study. Second, as in all similar phylogenetic studies, our re-
sults potentially depend on how phylogenetic clusters are
defined; here we have focused on monophyletic pairs of pa-
tients (irrespective of the statistical support for the cluster-
ing). However, we found similar results if we restricted the
analysis to pairs with high support values (i.e. where the
clustering was strongly supported by the phylogeny, see
Results), and if we extended the analysis beyond pairs (see
supplementary material available as Supplementary data at
IJE online). Finally, these results stem from the particular
epidemiological setting of the SHCS, and similar analyses
in other cohorts are required to assess the generalizability
of these findings.
Our results have several implications for public health.
The strong clustering of Swiss HCV that we found for all
transmission groups implies that the location of an HIV-1
infected patient on the HIV phylogeny can be used as a
measure of that patient’s risk of acquiring an HCV infec-
tion. Furthermore, the clustering indicates an important
role of domestic HCV transmission in the Swiss HCV epi-
demic, which in turn suggests that preventive interventions
can limit the spread of HCV even if they are locally limited
to Switzerland. The fact that this pattern was also observed
for MSM suggests that domestic transmission occurs for
sexually transmitted HCV as well. Specifically, we found
that MSMs paired with HCV-positive partners have a
more than 2-fold higher HR of acquiring HCV themselves,
highlighting the importance of safe sex practices in
HCV-discordant MSM couples and in sex with unknown
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partners even if HIV is suppressed by highly active anti-
retroviral therapy (HAART).
Supplementary Data
Supplementary material is available as Supplementary data at IJE
online.
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